In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.
8 Jan, 2022 | 22:37h | UTCCommentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD
Related: